Objectives: Survival in HNSCC has been associated with gender. It is unclear if this disparity in outcome is rooted in tumour biology. We compare mutation profiles between HNSCC arising in males and females.
Methods: Single nucleotide variation (SNV) and gene expression level (GEL) differences between males and females were compared within HPV-positive (n=67) and negative (n=431) TCGA HNSCC cohorts. Five-year overall survival was analyzed.
Results: Females were found to have poorer overall survival than males (p=0.048). Over twenty genes were found to have significantly different SNV between genders across cohorts on univariate analysis (p<0.05). BRWD3 (in the HPV negative cohort) was significantly different on multivariate analysis (p=0.02). Across cohorts, GEL was significantly different between genders in over fifty genes (p<0.05).
Conclusions: Females were shown to have poorer overall survival than males in HNSCC. Significant differences in mutation status and expression level were found for a multitude of genes.
At the conclusion of this presentation, Otolaryngologists should be able to:
- Describe differences in HNSCC outcomes between males and females
- Understand the amount of data contained within the TCGA database
- Understand the analysis of TCGA data and its correlation to clinical outcome
- Appreciate the genetic basis behind tumour development and behaviour between genders
Download Presentation Slides (PDF)
Authors' Contact Details
Corresponding Author: Dr. Neil Mundi
Senior Author: Dr. Anthony Nichols
The corresponding author of this presentation has not yet consented to having their email address published online.